Tag Archives: Tim Anderson

Merck’s Keytruda aces another cancer trial as results dazzle researchers

The News: Hot on the heels of the final presentation at ASCO’s 4-day conference in Chicago, a small, new study is causing jaws to drop after it found that a… Read more »

Novartis 1Q results remain insomnia cure; investors plead for something, anything to get excited about

The News: Novartis AG shares moved higher Tuesday (April 25, 2017) after the pharmaceuticals group clung to full-year earnings targets and barely beat analysts’ estimates for first-quarter earnings. The Swiss… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Bristol-Myers plunges, Merck buoyed on cancer-drug news; is it still dash for cash, or race to nowhere?

The News: Bristol-Myers Squibb Co. (New York City) won’t seek accelerated approval of its immunotherapy drug Opdivo for lung cancer, confirming that Merck & Co. (Kenilworth NJ) will have a huge head start… Read more »

Healthcare stocks primed for comeback in 2017? Here are Steve’s top picks

The population of the world, and the US and developed nations in particular, is growing and getting older, while the costs of keeping people healthy and living longer are exploding…. Read more »

Pfizer misses 3Q views but gets nod for Prevnar from China; Mao would scowl, but not Xi

More than a year after pulling its vaccines out of one of the world’s most challenging but lucrative drug markets, Pfizer has moved back into China with a thumbs up for top-selling… Read more »

Bristol Myers Clobbered as Cancer Drug Disappoints; Rival Merck Unanimous Winner at Medical Conference

New data are likely to prompt doctors to abandon Bristol-Myers Squibb Co.’s (New York City) immunotherapy Opdivo in favor of Merck & Co.’s (Kenilworth NJ) rival Keytruda in a large… Read more »